✦ LIBER ✦

Cox-2 inhibition for the treatment of colon cancer

✍ Scribed by Carlos Becerra

Publisher: John Wiley and Sons
Year: 2004
Tongue: French
Weight: 30 KB
Volume: 110
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.20071

No coin nor oath required. For personal study only.

✦ Synopsis

Aguilar and associates state that the dose of rofecoxib used in our clinical study is insufficient based on experiments in OFA rats whereby the best dose to reduce or prevent colorectal cancer is at least 2.5 mg/kg/day. This dose would represent 3-4-fold increase in the dose given to patients in the Phase II study. Unfortunately, one of the toxicities encountered in the study with the combination of 5-FU, Leucovorin and rofecoxib was gastrointestinal bleeding that would prevent investigators from further escalating the dose of rofecoxib. With more selective COX 2 inhibitors or utilizing chemotherapy combinations that are less damaging to the gastrointestinal mucosa investigators might be able treat patients with colorectal cancer and detect antitumor activity beyond that of the chemotherapy agents.

📜 SIMILAR VOLUMES

COX-2 and colon cancer: Potential target

COX-2 and colon cancer: Potential targets for chemoprevention

✍ David B. Fournier; Gary B. Gordon 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Evidence derived from several lines of investigation suggest that prostaglandins, metabolites of arachidonic acid, play an important role in colon cancer development. Elevated prostaglandin levels are found in colon cancers and their precursor lesions, adenomatous polyps. Agents such as aspirin and

Is COX-2 inhibition a panacea for cancer

Is COX-2 inhibition a panacea for cancer prevention?

✍ Harri Vainio 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 46 KB

The epidemiologic evidence and rodent studies suggest strongly that nonselective inhibitors of cyclooxygenase (COX) enzymes such as aspirin, inhibiting both COX-1 and COX-2 isoforms, reduce the incidence of and mortality from intestinal tumors. Genetically manipulated animals show that both Cox-1 an

Treatment of cancer of the colon

✍ H. Ramesh; P. G. Thomas 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

Tumor invasiveness and liver metastasis

Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2–selective inhibitor, etodolac

✍ Wei-Shone Chen; Sung-Jen Wei; Jacqueline Ming Liu; Michael Hsiao; Jen Kou-Lin; W 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 131 KB 👁 2 views

Subtotal colectomy or colonic preservati

Subtotal colectomy or colonic preservation in the treatment of colonic cancer?

✍ B. J. Moran; A. A. Jackson; S. J. Karran 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

Enhanced expression of cyclooxygenase (C

Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression

✍ Yuko Higashi; Takuro Kanekura; Tamotsu Kanzaki 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 2 views

Cyclooxygenase (COX)-2 is one of the rate-limiting enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. Recent studies have shown enhanced expression of COX-2 in cancer cells of several tissues. We investigated the expression of COX-2 and prostaglandin (PG) E 2 prod